[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509575":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":32,"collaborators":7,"id":35,"slug":7,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":7,"eligibilityCriteria":39,"healthyVolunteers":36,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":55,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Gaurav Goyal, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","1-866-438-1640","histio@uabmc.edu",[18],{"facility":5,"status":19,"city":20,"state":21,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"RECRUITING","Birmingham","Alabama","35233","United States",{"type":25,"coordinates":26},"Point",[27,28],-86.80249,33.52066,{"lat":28,"lon":27},[31],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"type":11,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Gaurav Goyal","Principal Investigator","100509575",false,"NCT05915208","Histiocytic Disorder Follow-up Study","Inclusion Criteria:\n\n* diagnosis of histiocytic disorder at any age\n\n  1. Langerhans cell histiocytosis,\n  2. Erdheim-Chester disease,\n  3. Rosai-Dorfman disease,\n  4. Xanthogranuloma,\n  5. Mixed histiocytosis\n  6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)\n  7. Hemophagocytic lymphohistiocytosis\n\nExclusion Criteria:\n\n* None","ALL","0 Years","89 Years",{"count":44,"type":45},6000,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders",[49,50,51,52,53,54],"Histiocytosis","Langerhans Cell Histiocytosis","Erdheim-Chester Disease","Rosai Dorfman Disease","Xanthogranuloma","Malignant Histiocytoses",[56,57,58,59],"survivorship","long-term","targeted therapy","second cancer","2026-06-10",{"date":62,"type":63},"2026-06-12","ACTUAL",{"date":65,"type":63},"2022-09-01",{"date":67,"type":45},"2028-12",{"name":5,"class":6},1]